(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 May 2015 (21.05.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/073231 A9

(51) International Patent Classification:
A61K 31/435 (2006.01) *A61K 31/44* (2006.01)
A61P 43/00 (2006.01) *A61K 31/47* (2006.01)

(21) International Application Number:
PCT/US2014/063506

(22) International Filing Date:
31 October 2014 (31.10.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/903,010 12 November 2013 (12.11.2013) US
61/929,604 21 January 2014 (21.01.2014) US
62/000,659 20 May 2014 (20.05.2014) US

(71) Applicant: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 50 Northern Avenue, 15th Floor, Boston, MA 02210 (US).

(72) Inventors; and
(71) Applicants : **SWINNEY, Kelly, Ann** [US/US]; 509 E. 2nd Street, Unit 8, Boston, MA 02127 (US). **HURTER, Patricia, Nell** [US/US]; 49 Tahanto Trail, Harvard, MA 01451 (US). **NADIG, David, E.** [US/US]; 150 Dorchester Avenue, Apt. 102, Dorchester, MA 02127 (US). **SMITH, David** [US/US]; 72 Parker Avenue, Newton, MA 02459 (US). **THOMAS, Vance, Hayden** [US/US]; 3 Pheasant Hill Lane, Duxbury, MA 02332 (US). **WARMAN, Martin, Paul** [US/US]; 1 Bradley Woods Drive, Hingham, MA 02043 (US).

(74) Agents: **IRVING, Thomas L.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, DC 20001-4413 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
16 July 2015

(15) Information about Correction:
see Notice of 16 July 2015

WO 2015/073231 A9

(54) Title: PROCESS OF PREPARING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES

(57) Abstract: Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2- difluorobenzo[d][1,3] dioxol-5 -yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5- hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.